Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Inflammatory Bowel Disease Diagnostic Receives FDA Approval



The clinical diagnostic could help differentiate IBD from the closely-related irritable bowel syndrome (IBS).

Share this!

November 17, 2016 | by Sarah Hand, M.Sc.

The US Food and Drug Administration (FDA) has approved Inova Diagnostics’ assay, QUANTA Lite Calprotectin Extended Range, to help physicians diagnose inflammatory bowel disease (IBD). The clinical diagnostic could help differentiate IBD from the closely-related irritable bowel syndrome (IBS).

“We are very pleased to launch this high performing assay to meet the increasing demand from laboratories worldwide,” said Dr. Michael Mahler, Vice President of Research and Development for Inova Diagnostics. “Gastrointestinal pain is a common reason for seeking medical attention. Inaccurate diagnosis at the screening level can contribute to unnecessary procedures and increased healthcare costs. QUANTA Lite Calprotectin Extended Range can improve care while helping reduce costs.”

By measuring calprotectin levels, physicians can determine the best treatment option from a patient suffering from a gastrointestinal disorder. Inova’s QUANTA Lite Calprotectin Extended Range using a quantitative enzyme linked immunosorbent assay (ELISA) to accurately detect calprotectin.

When used in combination with other clinical and laboratory tests, the diagnostic could help in the diagnosis of IBD, including Crohn’s disease and ulcerative colitis. Compared to other FDA-approved assays, QUANTA Lite Calprotectin Extended Range can detect a broader range of calprotectin levels.

“Fecal calprotectin has revolutionized my clinical practice in two specific areas,” said Dr. KT Park, Chair of Clinical Care and Quality, NASPGHAN and Co-Director, Stanford Children's IBD Center at Stanford University School of Medicine. “First, calprotectin measurements during patients' diagnostic workup, particularly when the diagnosis could be either IBS or IBD, provide direction and important information prior to endoscopic evaluations.

“Second, calprotectin follow-up testing in IBD patients supports a patient-centered, proactive approach to disease management, allowing accurate detection of indolent and often-missed inflammation. The improvements in quantitative range represented by Inova Diagnostics' new, FDA cleared assay is an update to the clinicians' toolkit for decision-making.”

Keywords: IBD, Diagnostic, FDA


Share this with your colleagues!

Researchers Identify Role of ApoE4 Gene as Possible Drug Target in Alzheimer’s Disease

September 21, 2017 - A team of neurology researchers at Washington University School of Medicine in St. Louis have found that in the presence of the ApoE4 protein, another protein known as tau forms tangles in the brain which contributes to neuronal damage characteristic of Alzheimer’s disease.

Featured In: Life Science News

New Guidelines Address CAR-T Immunotherapy Toxicities to Prevent Patient Deaths

September 20, 2017 - Clinicians at The University of Texas MD Anderson Cancer Center have published new guidelines in the journal, Nature Reviews Clinical Oncology, which could help in the management of these toxicities.

Featured In: Biotech News, Drug Safety News

Microneedle Skin Patch Could Treat Common Metabolic Disorders

September 19, 2017 - Researchers at Columbia University Medical Center (CUMC) and the University of North Carolina have developed a microneedle skin patch impregnated with a drug capable of converting white fat into calorie-burning brown fat.

Featured In: Medical Device News


Five Reasons Why Toronto is Emerging as a Major Life Sciences Hub


Development and Manufacture of Highly Potent API Drug Products Throughout the Clinical Phases

Innovation through Integration – Providing Next Generation Biomedical Devices and Interconnects

Clinical Payments Case Studies: Improving Efficiency, Cash Management, and Compliance

Why Phase 3 Trials Fail: Oncology Case Studies and Lessons Learned

Copyright © 2016-2017 Honeycomb Worldwide Inc.